Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor

被引:6
|
作者
Nixon, Donald R. [1 ,2 ,3 ,4 ]
Flinn, Nicholas [1 ]
机构
[1] Trimed Eye Ctr, Barrie, ON L4M 4S5, Canada
[2] Royal Victoria Reg Hlth Ctr, Dept Surg, Barrie, ON, Canada
[3] Soldiers Mem Hosp, Dept Surg, Orillia, ON, Canada
[4] Northern Ontario Sch Med NOSM, Dept Surg, Sudbury, ON, Canada
来源
CLINICAL OPHTHALMOLOGY | 2021年 / 15卷
关键词
contrast sensitivity; residual deficit; functional impairment;
D O I
10.2147/OPTH.S304229
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: What is the level of visual function in patients with diabetic macular edema (DME) and retinal vein occlusion (RVO) post-stabilization with anti-vascular endothelial growth factor? Patients and Methods: This observational non-controlled single center study evaluated visual function in two patient populations with macular edema 25 with diabetic macular edema and 25 with retinal vein occlusion treated following standard protocol of anti-VEGF therapy post- stabilization. Results: A total of 68 eyes from 50 patients were analyzed including 18 bilateral and 7 unilateral diabetic macular edema, 14 patients with central and 11 with branch retinal vein occlusion. The mean age was 69 +/- 11 years and 64% were male. In the RVO group: LogMAR BCVA was 0.12 +/- 0.13 compared to the unaffected eye 0.04 +/- 0.05 (P=<0.01), contrast sensitivity in the treated eye was 1.69 +/- 0.21 log units compared to 1.84 +/- 0.15 log units in the unaffected eye (p=<0.01), the ganglion cell volume was 0.88 +/- 0.15 mm(3) in the treated eye compared to 1.04 +/- 0.1 mm(3) in the unaffected eye (P=<0.01). In the diabetic macular edema group: LogMAR BCVA was 0.17 +/- 0.13, contrast sensitivity in the treated eye was 1.16 +/- 0.21 log units compared to the normal population 1.92 +/- 0.8 log units (p=<0.01), the ganglion cell volume was 0.94 +/- 0.14 mm(3) in the treated eye compared to 1.03 +/- 0.12 mm(3) in the normal population (P=<0.001). In both groups a majority of treated eyes retained visual acuity >=+0.4 LogMAR (diabetic macular edema 95%, RVO 96%) however contrast sensitivity was more than two standard deviations below the normal population mean in a majority of treated eyes in both groups (diabetic macular edema 88% RVO 64%). Conclusion: Impairment in contrast sensitivity in both groups could impact activities of daily living including driving and should prompt questions about how we advise patients regarding their level of function and the potential limitations/restrictions that should be placed on such activities.
引用
收藏
页码:1659 / 1666
页数:8
相关论文
共 50 条
  • [1] Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion
    Braithwaite, T.
    Nanji, A. A.
    Greenberg, P. B.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (10):
  • [2] Anti-vascular endothelial growth factor agent reduces inflammation in macular edema with central retinal vein occlusion
    Mashima, Asako
    Noma, Hidetaka
    Yasuda, Kanako
    Goto, Hiroshi
    Shimura, Masahiko
    JOURNAL OF INFLAMMATION-LONDON, 2019, 16 (1):
  • [3] Anti-vascular endothelial growth factor agents reduce inflammation in central retinal vein occlusion with macular edema
    Noma, Hidetaka
    Yasuda, Kanako
    Shimura, Masahiko
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [4] Anti-vascular endothelial growth factor agent reduces inflammation in macular edema with central retinal vein occlusion
    Asako Mashima
    Hidetaka Noma
    Kanako Yasuda
    Hiroshi Goto
    Masahiko Shimura
    Journal of Inflammation, 16
  • [5] Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema
    Kiss, Szilard
    Liu, Ying
    Brown, Joseph
    Holekamp, Nancy M.
    Almony, Arghavan
    Campbell, Joanna
    Kowalski, Jonathan W.
    CLINICAL OPHTHALMOLOGY, 2014, 8 : 1611 - 1621
  • [6] The Impact of Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Systematic Review
    Patil, Nikhil S.
    Mihalache, Andrew
    Dhoot, Arjan S.
    Popovic, Marko M.
    Muni, Rajeev H.
    Kertes, Peter J.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2023, 54 (01): : 50 - 58
  • [7] Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion
    Mitry, Danny
    Bunce, Catey
    Charteris, David
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (01):
  • [8] Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion
    Shalchi, Zaid
    Mahroo, Omar
    Bunce, Catey
    Mitry, Danny
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (07):
  • [9] Anti-vascular endothelial growth factor therapy for diabetic macular edema
    Boyer, David S.
    Hopkins, J. Jill
    Sorof, Jonathan
    Ehrlich, Jason S.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2013, 4 (06) : 151 - 169
  • [10] Anti-vascular endothelial growth factor treatment in diabetic macular edema
    Kim, Moosang
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1355 - 1356